AIMS-2-TRIALS has received the largest grant ever given for autism research. Its total value is composed of money and ‘in-kind’ contributions. The in-kind contributions are not actual money and instead include access to research data, expertise and skills, and staff time. Together, these contributions are all worth €113 million.

The programme’s main financial funder is the Innovative Medicines Initiative (IMI), who have provided almost €55 million. The in-kind contributions that come from charities and associated partners are worth €55.6 million, and those from industry partners are worth €2.6 million. For a complete break-down of the financial and in-kind contributions, visit the IMI’s fact-sheet about AIMS-2-TRIALS.

The Innovative Medicines Initiative

The IMI is the world’s largest public-private partnership (PPP; a partnership between public bodies and companies) in the life sciences. It is funded by the European Union (who are represented by the European Commission) and the European pharmaceutical industry (who are represented by EFPIA, the European Federation of Pharmaceutical Industries and Associations).

The IMI aims to improve health by speeding up the development of new medicines, particularly where there are unmet medical or social needs. To do this, it brings together the key players in healthcare research, such as universities, research centres, the pharmaceutical and other industries, small and medium-sized enterprises (SMEs), patient organisations, and medicines regulators.

Allocation of Funds and Resources

The €55 million that has been provided by the IMI will be allocated to the public partners that are in the programme’s team. The IMI’s funding is not available to industry. The public partners include universities, research organisations, public bodies and not-for-profit groups.

Learn more about the IMI via this video from the IMI’s 10th anniversary video series: ‘The Story of the Innovative Medicines Initiative’.